Pilot safety evaluation of doxorubicin chemotherapy combined with non-specific immunotherapy (Immunocidin®) for canine splenic hemangiosarcoma

Canine splenic hemangiosarcoma (HSA) is an aggressive tumor with a short overall survival time (OST) despite treatment with splenectomy and adjuvant doxorubicin. Modulation of the immune system has been shown to be effective for a variety of human tumors, and may be effective for canine tumors, incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Musser, Margaret L., Coto, Giovanna M., Lingnan, Yuan, Mochel, Jonathan P., Johannes, Chad M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778498/
https://www.ncbi.nlm.nih.gov/pubmed/36548371
http://dx.doi.org/10.1371/journal.pone.0279594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778498/
https://www.ncbi.nlm.nih.gov/pubmed/36548371
http://dx.doi.org/10.1371/journal.pone.0279594

Ejemplares similares